Influence of C. parvum on the effectiveness of passive serotherapy in the control of the EL4 lymphoma in C57BL/6 mice.
Administration of C. parvum alone did not improve the survival of C57BL/6 mice injected with the EL4 lymphoma. The anti-tumour effect of anti-EL4 Ig was however increased by C. parvum treatment, and the combination therapy of anti-EL4 Ig and cytotoxic drugs was even more improved. However, C. parvum only had this effect when given by the same i.p. route as the tumour cells, and the effect was greater when C. parvum was injected 5 days before than 1 day after tumour cells.
D000818:Animals; D003561:Cytarabine / Q000627:therapeutic use; D004306:Dose-Response Relationship, Immunologic; D007106:Immune Sera / Q000008:administration & dosage; D007116:Immunization, Passive; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy; D011425:Propionibacterium acnes / Q000276:immunology*
D007106:Immune Sera; D003561:Cytarabine